Research ArticleHuman Studies
Phase 1 Study of Rhenium-186-HEDP in Patients with Bone Metastases Originating from Breast Cancer
John M.H. de Klerk, Alfred D. van het Schip, Bernard A. Zonnenberg, Aalt van Dijk, Jac M.S.P. Quirijnen, Geert H. Blijham and Peter P. van Rijk
Journal of Nuclear Medicine February 1996, 37 (2) 244-249;
John M.H. de Klerk
Alfred D. van het Schip
Bernard A. Zonnenberg
Aalt van Dijk
Jac M.S.P. Quirijnen
Geert H. Blijham
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Phase 1 Study of Rhenium-186-HEDP in Patients with Bone Metastases Originating from Breast Cancer
John M.H. de Klerk, Alfred D. van het Schip, Bernard A. Zonnenberg, Aalt van Dijk, Jac M.S.P. Quirijnen, Geert H. Blijham, Peter P. van Rijk
Journal of Nuclear Medicine Feb 1996, 37 (2) 244-249;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Phase 2 Study of a High Dose of 186Re-HEDP for Bone Pain Palliation in Patients with Widespread Skeletal Metastases
- Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseous Metastases
- Advances in radionuclide imaging: radionuclide imaging as a guide to therapy
- Marrow-Sparing Effects of 117mSn(4+)Diethylenetriaminepentaacetic Acid for Radionuclide Therapy of Bone Cancer
- Quantitative Bone Single-Photon Emission Computed Tomography for Prediction of Pain Relief in Metastatic Bone Disease Treated With Rhenium-186 Etidronate